Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
FEI Company
FEI and Sidec tackle validation of drug targets
April 8th, 2006
FEI Company (FEIC) and Sweden-based Sidec Technologies AB announced that the two companies will collaborate on the commercialization of Protein Tomography solutions and services based on Sidec's proprietary software and intellectual property, and FEI's transmission electron microscopes (TEMs). Protein Tomography is a new technology developed to address critical issues around drug target validation and translational medicine in the pharmaceutical industry, improving target validation processes and shortening development time for new pharmaceuticals. Based on current market practices, Protein Tomography is estimated to be a US$200 million market with the potential to grow...
Source: Law & Health Weekly (2006-04-08)
|
